Consensus and controversy in postoperative thyroid stimulating hormone suppression therapy for differentiated thyroid carcinoma

Abstract

Differentiated thyroid carcinoma (DTC) is the most common thyroid carcinoma, with a generally favorable prognosis for most patients. At present, Surgery, 131I and thyroid stimulating hormone (TSH) suppression are the main therapeutic means among which, TSH suppression therapy plays an important role in the postoperative management of DTC patients, which has the effect of decreasing the risk of recurrence, slowing down the progression of the disease, and improving long-term survival. However, excessive TSH suppression can increase the risk of adverse events in the cardiovascular and skeletal systems. Currently, there is ongoing debate regarding the optimal target range for serum TSH suppression in patients of all types. In clinical practice, it is important to carefully balance the benefits and potential risks of TSH suppression, and to personalize the target range for serum TSH based on dynamic assessments during patient follow-up. This article aimed to discuss the intensity, benefits, and risks of TSH suppression after surgery for DTC patients, as well as the current controversies about this topic.

Keywords

• |differentiated thyroid carcinoma|postoperative management|thyroid stimulating hormone suppression therapy